Unicycive Therapeutics’ $50 Million Private Placement

Sheppard Mullin advised Unicycive Therapeutics in the transaction.Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, executed its $50 million…